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ABSTRACT  
The delivery of therapeutic molecules to the central nervous system is hampered by poor delivery across 
the blood-brain barrier (BBB). Several strategies have been proposed to enhance transport into the brain, 
including invasive techniques and receptor-mediated transport (RMT). Both approaches have several 
drawbacks, such as BBB disruption, receptor saturation and off-target effects, raising safety issues. 
Herein, we show that specific domains of Dengue virus type 2 capsid protein (DEN2C) can be used as 
trans-BBB peptide vectors. Their mechanism of translocation is receptor-independent and consistent 
with adsorptive-mediated transport (AMT). One peptide in particular, named PepH3, reaches 
equilibrium distribution concentrations across the BBB in less than 24 hours in a cellular in vitro assay. 
Importantly, in vivo biodistribution data with radiolabeled peptide derivatives shows high brain 
penetration. In addition, there is fast clearance from brain and high levels of excretion, showing that 
PepH3 is a very good candidate to be used has a peptide shuttle taking cargo in and out the brain. 
KEYWORDS Translocation peptides; drug delivery systems; blood-brain barrier; neurotherapies. 
BRIEFS Peptides obtained from selected sequences of the Dengue Virus type 2 capsid protein have the 
ability to translocate the blood-brain barrier.  
MANUSCRIPT TEXT 
INTRODUCTION 
Due to aging and other societal factors the prevalence of neurological disorders is growing and is 
presently a public health priority and an important cause of mortality: 12 % of total deaths worldwide 
1
. 
Despite rapid developments in understanding brain function and the great advances in medical 
technology, many central nervous system (CNS)-associated malignancies, remain devastating and 
poorly treated 
2
. The reasons for the low success rates of CNS-targeted treatments are mainly related to: 
incomplete understanding of the brain biochemistry and physiology; the high susceptibility for side 
effects; shortage of validated biomarkers for assessing therapeutic efficacy; and poor delivery to the 
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brain. The main hurdle for effective CNS drug delivery is the blood-brain barrier (BBB), formed by 
brain endothelial cells richly connected by tight junctions that selectively limit the transfer of substances 
between the blood and the interstitial fluid of the CNS, and vice versa 
3
. It is estimated that 
approximately 98 % of small molecules and nearly all large molecules, such as recombinant proteins or 
gene-based medicines 
4
 are unable to cross the BBB. BBB disruption or transient opening 
5
 is a 
possibility to overcome this limitation but these invasive strategies remain technically challenging and 
raise safety concerns 
6
. Hence, effective and safe alternative approaches should be carefully designed to 
avoid compromising the overall protective function of BBB 
7
.  
Compounds that are able to traverse the BBB may use active or passive mechanisms. Small lipophilic 
molecules tend to enter the brain by passive diffusion. Nutrients such as glucose and amino acids use 
specific carriers present on endothelial membranes to be transported to the brain. In contrast, larger 
molecules (e.g. peptides and proteins) able to transverse the BBB are transported either via receptor-
mediated transcytosis (RMT) or adsorptive-mediated transcytosis (AMT). Peptides, modified proteins or 
monoclonal antibodies may explore both entry routes 
8
. RMT pathways carry macromolecules such as 
insulin, leptin and transferrin into the brain 
9
. Engineered ligands that explore RMT are known as 
“Molecular Trojan horses”, which can bind BBB receptors and deliver therapeutic molecules across the 
BBB 
10-12
. The efficiency of transport across the BBB, however, is limited by the number of receptors 
exposed in brain endothelial cells (BEC’s) and poor penetration of drugs into the brain 
9
.The transferrin 
and the insulin receptors (TfR and IR, respectively) are examples of well-studied receptors for brain 
targeting, however, are highly and broadly expressed in other tissues and are also implicated in crucial 
cellular functions, creating safety risks 
13-14
. Over the past years there has been an effort to identify new 
BBB RMT targets that have better BBB specificity. For example, the heavily glycosylated protein 
Cdc50A, recognized by the FC5 single domain antibody selected by functional panning of llama VHH 
phage-display library, is internalized into BEC’s 
15
. Biodistribution assays reveal high brain uptake: 2.9 
% injected dose per gram of tissue (ID/g of tissue) 
16
. Recent work from Zuchero et al, reveals other 
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adequate receptors for BBB-specific RMT, such as basigin, Glut1 and CD98hc, the latter enabling 
considerable accumulation in the brain (0.4 % ID/g of tissue) of radiolabeled antibodies 
17
. In addition, 
by using bispecific antibodies that bind to CD98hc on one arm, and the amyloid precursor protein (APP) 
cleavage protein enzyme β-secretase (BACE1) on the other arm it was possible to translocate the BBB 
and reduce Aβ production 
17
. This method is, however, complex and critically dependent on very few 
and specific receptors. Besides, there is still a lack of information on the expression of these receptors in 
other tissues and the general safety profile.  
New approaches that overcome the limitations of RMT are urgently needed. AMT is a suitable 
alternative. AMT is mainly triggered by electrostatic interaction of cationic proteins or peptides with 
endothelial cells 
18-19
. Peptide vectors for AMT are typically cationic due to the presence of lysine and 
arginine residues in their composition. They can also combine polar and non-polar/hydrophobic amino 
acid residues to form amphipathic domains that facilitate cellular uptake. Several examples of receptor-
independent peptide vectors include the trans-activating transcriptional activator (TAT) from the human 
immunodeficiency virus 1 (HIV-1), the third helix of Antennapedia homeodomain (Antp) and SynB1 
derived from protegrins; among others 
20-21
. These peptides deliver different cargos across a variety of 
endothelial cells, including BEC’s 
22
. For instance, SynB1 and D-penetratin were used to deliver 
doxorubicin to the brain, using in situ rat brain perfusion 
23
. Furthermore, TAT was fused to β-
galactosidase (β-gal) and administered to mice. β-gal activity in the brain was detected without affecting 
the integrity of the BBB 
24
. A recent study has also shown the uptake of angiopep-2 paclitaxel conjugate 
into the brain with improved delivery to brain and brain metastases of breast cancer compared to free 
paclitaxel 
25
. 
Although the proof of concept has been validated for more than 15 years 
24
, the quest for efficient cost-
effective trans-BBB receptor-independent peptide-vectors remains. Recently we have shown that viral 
proteins are an underexplored source of peptide vector templates 
26
 as viruses have the ability to 
penetrate cells very efficiently. Some short sequences of the Dengue Virus Type-2 capsid protein 
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(DEN2C) are particularly efficient in cellular membrane translocation, one of them using receptor-
independent routes 
27-28
. DEN2C is a highly basic protein with the capacity to translocate cell 
membranes carrying macromolecules 
28-29
, which prompted us to carry out a systematic study of the 
helical domains of this protein as trans-BBB vectors. Translocation of the BBB by DEN2C derived 
peptides was tested both in vitro and in vivo. One domain, PepH3, achieved promising brain penetration 
as demonstrated by in vitro and in vivo studies.  
 
RESULTS  
Selection of peptide sequences. The viral genome of Dengue Virus (DENV) consists of a single-
stranded, positive sense RNA molecule that is complexed to multiple copies of the capsid protein 
(DEN2C). The nucleocapsid is surrounded by host-derived lipid membrane, in which two 
transmembrane proteins are inserted, the major envelop glycoprotein E and the membrane protein M 
30
. 
DEN2C protein is highly charged and its structure, determined by NMR, comprises four α-helical 
domains, α1, α2, α3 and α4 (Figure 1) 
27
. The protein forms a dimer in which the positive charges on the 
exposed regions of α4 have been assigned to have a role in electrostatic RNA binding, while the 
relatively hydrophobic α2 regions have been assigned to be putatively responsible for lipid membrane 
association, but this hypothesis has been challenged 
27
. The whole protein and two distinct sequences of 
amino acids of the protein, PepM (α2 – α3) and PepR (α4 and C-terminal region rich in arginine residues) 
have the capacity to deliver nucleic acids into cells 
29
. Herein, the isolated helical short domains α1, α2, 
α3, and α4 (PepH1, PepH2, PepH3 and PepH4, respectively) were studied as trans-BBB peptide-vectors. 
The peptides and their labeled radioactive analogs were synthesized and tested in in vitro brain 
endothelial barrier (BEB) models for translocation efficacy, followed by examination of brain 
penetration in vivo in CD1 mice. 
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Synthesis and characterization of radiopeptides. Firstly, PepH1 to PepH4 were prepared in an 
automated MW-assisted solid phase peptide synthesizer using the Fmoc strategy. The amino acid 
sequences, isoelectric point (PI), charge and mass, determined by Electrospray Ionisation-Mass 
Spectrometry (ESI-MS), for all peptides are displayed in Table 1.  
The peptide conjugates containing the pyrazol-diamine(Pz) (Pz
1
PepH1, Pz
1
PepH2, Pz
1
PepH3 and 
Pz
2
PepH4) and the NODA-GA (NODAPepH1 to NODAPepH4) chelating units (Table 1) were 
prepared by conjugation of the carboxylic acid of the respective bifunctional chelator (Pz
1
, Pz
2
 or 
NODA-GA) to the N-terminal of the peptides (PepH1 to PepH4) on the resin, as described in the 
experimental section. Following cleavage from the solid support and precipitation with ice-cold diethyl 
ether the crude peptide conjugates were purified by semipreparative RP-HPLC (> 95% purity). After 
lyophilization the pure peptide conjugates, obtained as white solids, were characterized by ESI-MS. 
Reaction of the peptide conjugates with the precursor fac-[
99m
Tc(CO)3(H2O)3]
+
 gave the corresponding 
radiolabelled peptides TcPz
1
PepH1, TcPz
1
PepH2, TcPz
1
PepH3 and TcPz
2
PepH4 in high 
radiochemical yield and purity (> 90 %) (Table 1). 
The 
67
Ga-labeled peptide conjugates (GaNODAPepH1 to GaNODAPepH4) were prepared in high 
radiochemical yield and purity (> 95 %) by reaction of the respective peptide conjugate with the 
precursor 
67
GaCl3 at room temperature for 5 min (Table 1). 
The octanol-water partition coefficients, Po/w, were determined for all radioactive peptide conjugates by 
the ‘‘shake flask’’ method (Table 1) to assess hydrophobicity 
31
.  The results show that radiolabeled 
PepH2 and PepH3 are the most hydrophobic. In addition, experiments using lipid membrane models 
(Supplementary Figure S1 and S2) containing phosphatidylcholine (PC), phosphatidylglycerol (PG), 
phosphatidylserine (PS) and cholesterol (Chol) show that PepH2 interacts to a greater extent with the 
zwitterioinic POPC and POPC:Chol bilayers followed by the anionic POPC:POPS and POPC:POPG 
bilayers. It has been proposed that cholesterol plays an important role in facilitating efficient cell entry 
of DENV and that infectivity can be significantly impaired in cholesterol-depleted cells 
32
. PepH3 has a 
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strong preference for anionic POPC:POPS (1:4) bilayers, presenting a lipid bilayer-water partition 
coefficient (Kp) of (1.6±0.2)×10
2
. In addition, both PepH2 and PepH3 present an α-helical conformation 
in the presence of LUV’s (Figure S2).  
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Table 1 – (Radio)peptide properties.  Peptide sequences, isoelectric point (IP), charge, molecular weight (MW), HPLC retention time, and 
octanol-water partition coefficients for all peptide derivatives.  
Peptide Sequence IP Charge 
Calcd 
exact 
mass 
(Da) 
Found [ion] 
Peptide 
conjugates 
Calcd 
exact mass 
(Da) 
Found [ion] 
tR  (min) 
tR (min) 
radiopeptides 
log Po/w  of 
radiopeptides 
Peptide 
conjugates 
PepH1 VQQLTKRFSL 11.0 2 1219.4 1220.4 [M+H]
+ 
Pz1PepH1 1527.8 1527,10 [M+H]
+ 12.1a TcPz1PepH1: 16.1a - 1.76 ± 0.11 
NODAPepH1 1576.6 789,10 [M+2H]
2+ 13.6b GaNODAPepH1: 13.8b -2.16 ± 0.04 
PepH2 KLFMALVAFLRFLT 11.0 2 1670.1 1671.1 [M+H]
+ 
Pz1PepH2 1978.4 1978,30 [M+H]
+ 20.2a TcPz1PepH2: 22.4a 0.65 ± 0.13 
NODAPepH2 2027.2 2027,80 [M+H]
+ 23.5b GaNODAPepH2: 23.7b 0.35 ± 0.14 
PepH3 AGILKRW 11.0 2 843.0 844.0 [M+H]
+ 
Pz1PepH3 1151.3 1151,80 [M+H]
+ 13.5a TcPz1PepH3: 15.9a 0.11 ± 0.06 
NODAPepH3 1200.2 1200,00 [M+H]
+ 13.4b GaNODAPepH3: 13.7b 1.21 ± 0.09 
PepH4 KSKAINVLRGFRKEIGRMLNILN 11.7 6 2671.2 1336.0 [M+2H]
2+ 
Pz2PepH4 2934.5 735,40 [M+H]
+ 10.6a TcPz1PepH4: 12.8a -1.84 ± 0.31 
NODAPepH4 3027.4 1010,14 [M+3H]
3+ 18.2b GaNODAPepH4: 18.4b -0.80 ± 0.13 
                        
a
 Gradient D; 
b
 Gradient E 
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Integrity of the BEB model. The in vitro BEB model was prepared using brain endothelial cells 
(bEnd.3) growing in tissue culture inserts (Figure 2A). bEnd.3 is an immortalized mouse brain 
endothelial cell line with barrier properties, which are widely used as a model for the BBB due to their 
rapid growth, the maintenance of their properties over repeated passages and amenability to numerous 
molecular interventions 
33-34
. The integrity of the endothelial barrier was evaluated through the 
permeability of 5(6)-carboxyfluorescein (FITC) and fluorescently labeled dextrans (FD) with different 
molecular weights (FITC - 376.32 Da, FD4 - 4 KDa, and FD40 - 40 KDa) (Figure 2B, C and D, 
respectively). The clearance of the fluorescent probes from the apical side in the presence or absence of 
the unlabeled peptides (1 µM) was negligible, which demonstrates the lack of both fenestration in the 
cell barrier and paracellular leakage. Small molecules such as FITC have a residual crossing of the 
cellular model of the BEB but molecules with higher molecular weight, such as FD4 or FD40, have 
negligible translocation. In addition, cell viability assays show that the fraction of viable bEnd.3 cells 
was above 90 %, even at 100 µM peptide concentration (Supplementary Figure S3). 
Translocation across the BEB. To study the kinetics of the radiopeptides transmigrating through the in 
vitro BEB model, 5 µCi mL
-1
 of radiopeptide (TcPz
x
PepH1 to TcPz
x
PepH4, x = 1 or 2) were added to 
the apical chamber. The apical side (apex) volume, transwell filter covered with cell and base volume 
were collected after 15 min, 5 h and 24 h (Figure 3A to D) and the radioactivity in those samples 
measured separately in a γ-counter. Complementary experiments were performed to determine the 
fraction of peptides associated to bEnd.3 cell membrane and intracellular space (Figure 4A to D). In this 
case, cells growing in 24-well plates were incubated with the radiopeptides, washed with an acid buffer 
to assess the interaction with cell membrane; and finally cells were lysed to determine the cellular 
internalization. The radioactivity associated to each fraction was then measured in the γ-counter. 
The data obtained demonstrated that PepH1 was able to transmigrate the BEB, with up to 73.8±9.4 % of 
the peptide radioactivity found in the base after 24 h (Figure 3A). In addition, PepH1 had minimal 
internalization and membrane retention (0.12±0.00 and 0.38±0.10 %, respectively) (Figure 4A). BEB 
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translocation of PepH2 was reduced (9.2±2.5 % after 24 h), although it presented high cellular 
internalization (42.7±0.0 % after 24 h) (Figure 3B and 4B). Similar to PepH1, BEB translocation of 
PepH3 was high (67.2±1.2 % at 24 h) and the radioactivity associated to the cell (membrane and 
internalized peptide) was low (Figure 3C and 4C). In contrast to all other peptides, PepH4 had moderate 
membrane retention and low internalization (10.2±0.8 and 2.8±0.2 %, respectively) (Figure 3D) and 
high BEB translocation (63.4±1.9 % after 24h) (Figure 4D). It is worth highlighting that the volume of 
the base is 2.5-fold the volume of the apex. The amount of PepH1, PepH2, PepH3 and PepH4 is also 
2.5-fold in the base relative to the volume of the apex, which shows that there is an equilibrium in the 
distribution of the peptides across the BEB cells, consistent with AMT.  
In order to better assess the action of the peptide itself, independent from the radioactive label used, we 
carried out similar experiments with 
67
Ga-labeled peptides (Table S1). Table 2 compares the results 
obtained with the two different radioisotopes after 24 h incubation time, revealing very similar results 
for BEB translocation. Nevertheless, there are differences in the percentage of internalization and 
percentage of cellular adsorption for PepH2 and PepH4. The radiometal core influences the retention of 
peptides by cells. It is noteworthy that the net charge of the final radiopeptide is affected by the 
radiometal core. Indeed, in the case of 
99m
Tc, the radioactive metal core (fac-[
99m
Tc(CO)3]
+
) is stabilized 
by a neutral pyrazolyl-diamine chelating unit (Pz
x
) giving monocationic radiometal complexes 
35
, 
whereas in the case of 
67
Ga, the trivalent metal is stabilized by a trianionic macroclyclic chelator 
(NODA-GA), which results in neutral radiometal complexes 
36
.  
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Table 2 – Determination of BEB translocation, membrane adsorption and internalization of 
radiopeptides in bEnd.3 cells. Recovered radioactivity of peptides labeled with TcPz
x
 or GaNODA 
after 24 h incubation, in the base.   
  Recovered radioactivity in the base after 24 h (%) 
 
BBB transmigration 
 
Membrane adsorption 
 
Internalization 
Peptide   TcPz
x
 GaNODA   TcPz
x
 GaNODA   TcPz
x
 GaNODA 
PepH1 
 
73.83±9.40 71.47±3.70 
 
0.38±0.10 0.62±0.00 
 
0.12±0.00 0.16±0.00 
PepH2 
 
9.32±2.50 13.51±0.70 
 
2.20±0.40 1.16±0.10 
 
42.70±0.00 9.24±1.20 
PepH3 
 
67.23±1.20 72.63±0.70 
 
0.60±0.10 0.60±0.10 
 
0.35±0.20 0.30±0.10 
PepH4 
 
63.45±1.90 60.79±2.60 
 
10.23±0.80 3.82±0.10 
 
2.83±0.20 1.55±0.10 
          
 
Biodistribution studies.   
The radiopeptides TcPz
1
PepH1 and TcPz
1
PepH3 were the molecules with the most promising behavior 
in the in vitro experiments and were therefore selected for evaluation in vivo. They were administrated 
intravenously in CD1 mice and their biodistribution evaluated at two different time points (5 min and 1 
h). As a negative control, the biodistribution profile of TcPz
3
 was also evaluated in the same animal 
model to demonstrate the low ability of the radiometal core ([
99m
Tc(CO)3]
+
 stabilized by a model 
pyrazolyl-diamine containing chelator) to cross the BBB. The pharmacokinetic profile of the 
radiolabeled peptides was also compared with that of 
99m
Tc(CO)3-recombinant small domain antibody 
FC5 that has been previously demonstrated to efficiently penetrate de BBB using RMT 
16
. The 
biodistribution of TcPz
3
, TcPz
1
PepH1, TcPz
1
PepH3 and TcFC5 is shown in Table 3. The brain uptake 
of TcPz
1
PepH1 and TcPz
1
PepH3 peptides occurs rapidly after injection (> 0.1 % injected dose per gram 
of brain after 5 min). Importantly, the data obtained clearly demonstrates that the brain uptake for 
TcPz
1
PepH1 (0.14±0.03 %ID/g) and TcPz
1
PepH3 (0.31±0.07 %ID/g) at 5 min is, respectively, 1.6 and 
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3.4-fold higher than the brain accumulation of TcPz
3
 (0.09±0.01 %ID/g). These results clearly show that 
the biological BBB crossing activity of PepH1 and PepH3 can be assigned to the peptide sequence and 
not to the radiometal core. Moreover, both peptides have rapid brain washout (down to < 0.03 ±0.01 % 
ID/g after one hour), concomitant with fast elimination of the total radioactivity from most organs: 
radiopeptides were rapidly cleared from blood, liver, kidney, and highly irrigated organs, accumulating 
in the intestine (>10 %). Indeed, an important fraction of the activity was excreted (>30 %) 1 h after 
injection (Table 3). In addition, when we compare the pharmacokinetic profiles of Pz
1
PepH1 and 
TcPz
1
PepH3 peptides with the biodistribution profile of TcFC5 we can see that PepH3 showed a similar 
BBB crossing at 5 min post injection (0.47±0.27 % ID/g). Furthermore, PepH3 is rapidly excreted at 
higher percentages (36.0±11.2 % ID/g) when compared with TcFC5 (9.6±1.4 % ID/g), which is 
extremely positive to avoid toxic effects associated to accumulation in the brain and other organs. 
Brought together the in vivo results show that although TcPz
1
PepH1 displays a more modest brain 
accumulation, TcPz
1
PepH3 exhibited a robust brain uptake and can be a good candidate as a shuttle 
peptide for taking cargo in and out of the brain. 
 
Table 3 – Biodistribution profiles of 
99m
Tc(CO)3-labeled peptide-vectors and small domain 
antibody FC5. Tissue distribution of TcPz
3
, TcPz
1
PepH1, TcPz
1
PepH3 and TcFC5 at 5 min and 1 hour 
post injection via tail vein in CD1 mice. Results are expressed as the average of percentage of injected 
dose (ID) per gram of tissue (%ID/g tissue) (mean ± SD), n = 3.
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Percentage of injected dose per gram of tissue   (%ID/g) 
TcPz
3
 (Control) TcPz
1
PepH1  TcPz
1
PepH3 TcFC5 
Organ    5 min  1 h 5 min  1 h 5 min 1 h 5 min 1 h 
    
  
            
Blood   3.60 ± 0.20 0.23 ± 0.01 2.90 ± 0.90 0.40 ± 0.20 8.60 ± 0.90 0.43 ± 0.04 6.00 ± 0.40 1.00 ± 0.20 
Liver   12.90 ± 0.60 5.00 ± 0.60 10.70 ± 1.90 3.00 ± 1.20 18.80 ± 6.10 2.30 ± 0.20 21.00 ± 0.80 12.40 ± 0.40 
Intestine   2.40 ± 0.40 10.00 ± 1.40 4.60 ± 0.80 11.50 ± 1.50 1.40 ± 0.20 23.0 ± 7.90 3.50 ± 0.30 0.79 ± 0.04 
Spleen   0.75 ± 0.01 0.40 ± 0.20 0.80 ± 0.20 0.90 ± 0.20 1.60 ± 0.40 0.18 ± 0.01 4.60 ± 2.00 4.20 ± 0.80 
Heart   1.17 ± 0.07 0.70 ± 0.50 0.70 ± 0.20 0.13 ± 0.02 2.20 ± 0.30 0.14 ± 0.01 4.20 ± 0.80 0.76 ± 0.03 
Lung   2.00 ± 0.40 0.40 ± 0.30 3.30 ± 0.60 1.70 ± 0.40 4.48 ± 0.01 0.31 ± 0.03 16.10 ± 6.50 38.20 ± 6.20 
Kidney   21.10 ± 4.00 2.70 ± 0.40 7.20 ± 1.10 1.40 ± 0.50 23.10 ± 3.40 3.50 ± 0.70 20.80 ± 3.90 96.40 ± 6.80 
Muscle   0.68 ± 0.07 0.20 ± 0.06 0.50 ± 0.20 0.12 ± 0.01 1.40 ± 0.20 0.20 ± 0.10 0.90 ± 0.10 0.39 ± 0.04 
Bone   0.70 ± 0.10 0.19 ± 0.08 0.60 ± 0.10 0.10 ± 0.03 1.89 ± 0.04 0.19 ± 0.01 1.60 ± 0.10 0.80 ± 0.30 
Stomach   1.40 ± 0.50 0.32 ± 0.15 0.50 ± 0.30 0.24 ± 0.06 1.10 ± 0.20 5.20 ± 0.70 1.90 ± 0.30 0.80 ± 0.30 
Brain   0.09 ± 0.01 0.04 ± 0.01 0.14 ± 0.03 0.02 ± 0.01 0.31 ± 0.07 0.03 ± 0.01 0.47 ± 0.27 0.07 ± 0.02 
  
        
Excretion (%ID)   11.60 ± 3.70 42.80 ± 7.60 20.20 ± 5.30 55.10 ± 11.00 - 36.00 ± 11.20 - 9.60 ± 1.40 
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Chemical stability in blood and urine. The analysis of tissue samples collected from the sacrificed 
mice at 5 min and 1 h showed that radiopeptides are relatively stable in the blood but in urine they are 
partially degraded with new radiochemical species appearing at lower retention times after 1 h. Figure 5 
shows the RP-HPLC chromatograms of the radiolabeled peptides PepH1 and PepH3 before 
administration and in mice blood serum and urine collected 5 min and 1 h after administration. The 
peptides are stable in the blood but in urine they are partially degraded with new radiochemical species 
appearing at lower retention times after 1 h.  
 
DISCUSSION 
The capsid protein of Dengue virus type 2 (DEN2C) is able to translocate cell membranes carrying 
proteins and genes that remain functional in the intracellular space 
28-29
. This property has led to the 
hypothesis that capsid protein intervenes in the viral penetration of cells 
37-38
. Two distinct peptides, 
corresponding to two separate domains of DEN2C retain the cell-penetrating properties of the parent 
protein 
29
. Here, we performed a systematic study of the four highly structured helical domains of 
DEN2C, having the sequences of PepH1, PepH2, PepH3 and PepH4 peptides (Figure 1 and Table 1), 
aiming at: i) finding their efficacy in translocating the BBB, and ii) unraveling the mechanism of 
translocation of the most efficient domain peptide. Barrier translocation is a multi-step vectorial process, 
starting with interaction with the membranes of cells on one side and exit of the cell on the other side, a 
process known as transcytosis. The interaction with the membranes may be receptor-mediated (receptor-
mediated transcytosis – RMT) or consist in simple adsorption (adsorptive-mediated transcytosis – 
AMT). In both cases, RMT or AMT, efficient translocation across the barrier demands low entrapment 
inside cells. In this sense, not all cell-penetrating peptides are good translocators of cellular barriers and 
can be promising candidates to be used as BBB-crossing vectors. Cell-penetrating peptides that 
accumulate inside cells are not only low efficacy translocators, they also tend to accumulate in different 
organs and lead to undesired off-target effects. A study by Sarko et al 
39
, for instance, has shown that a 
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panel of cell-penetrating peptides, including penetratin, Tat, pVEC, R9 and SynB1 accumulate 
unspecifically in different cell lines (SW1736, PC3, MH wt, HNO 97, MCF7, and HCT 116) and, 
consequently, in different organs, such as heart and lung 
39
.  
In the present study, we have used a judicious combination of biophysical approaches in lipid vesicles, 
cellular models of the BEB and in vivo biodistribution studies to ascertain which of the DEN2C specific 
peptide domains shows the most promising properties to be used as a trans-BBB peptide vector. All 
peptides were used in concentrations not toxic to the bEnd.3 cells as demonstrated in the in vitro model 
of the BEB (Figure 2) and viability assays (Figure S3). Radiolabeled PepH1 and PepH3 peptides shown 
efficient translocators of the BEB, reaching equal distribution of peptides over the two compartments of 
the transwell setup 24 h after application at the apical side (Figure 3). In contrast, PepH2 heavily 
associates to cellular membranes and accumulates inside cells, concomitantly not being an efficient 
BBB translocator. PepH4 showed an efficient BEB translocation, nevertheless, the data also 
demonstrated that it had moderate membrane retention and higher internalization when compared with 
PepH1 and PepH3 (Figure 3 and 4).  
The ability to discriminate the anionic lipid PS on the surface of cells may explain these results in part. 
PepH2 has increased affinity for zwitterionic POPC and POPC:Chol lipid bilayers in contrast with 
PepH3, which has highest affinity for anionic POPC:POPS (1:4) bilayers (Supplementary Figures S1 
and S2). Ribeiro et al, showed that BEC are anionic, this being the key to the increased permeability of 
the BBB to cationic molecules 
40
. BEC membranes are more anionic than the membranes of blood cells 
(red blood cells, RBC, peripheral blood mononuclear cells, PBMCs, and platelets) and other endothelial 
cells (human umbilical vascular endothelial cells, HUVEC) 
40
. BEC are relatively rich in PS and 
phosphatidylinositol, PI, 
41
 which makes PepH3 a very strong candidate to translocate the BBB. This 
ability to screen for PS may be the key to the differences in BBB translocation efficiency as both PepH2 
and PepH3 have similar hydrophobicity (Po/w, Table 1) and adopt the same conformation in lipid 
membranes. Lipid-membrane-induced acquisition of secondary-level structure in peptides positively 
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correlates with propensity to translocate cell membranes 
42-43
. Again, our results reveal that both 
hydrophobic peptides, PepH2 and PepH3 interact bEnd.3 cell membranes, followed by internalization in 
the cell, yet their intercellular traffic pathway appears to be different, with PepH3 presenting high 
capacity to be delivered to the opposite side of the cell. While, PepH2 accumulates inside bEnd.3 cells. 
Molecular interaction with the cell membrane is thus a necessary, but not sufficient, condition for BBB 
translocation to occur. In fact, not all molecules that interact with membranes are cell-penetrating and 
not all cell-penetrating molecules are able to translocate cellular barriers. Therefore, hydrophobicity 
increases propensity of a peptide to interact with membranes but cannot be used to predict cell-
penetration or cell-translocation.  
It is worth mentioning that PepH3 BEB translocation is consistent with AMT. It is known that AMT is 
triggered by electrostatic interaction between polycationic molecules and anionic microdomains in 
BECs 
44
. Our data shows that PepH3, a polycationic peptide, interacts electrostatically with anionic cell 
membranes. Another result consistent with AMT is the fast kinetics of translocation: compared to RMT, 
AMT involves lower binding affinity but higher binding capacity 
45
, which grants faster kinetics to the 
translocation. 
Altogether, the in vitro data demonstrated that PepH1 and PepH3 were the most promising peptides and 
were therefore selected to be further studied in the in vivo biodistribution. The in vivo data showed that 
brain uptake was very fast (up to 5 min post injection) and efficient (up to 0.31±0.07 % ID/g for 
TcPz
1
PepH3), followed by a rapid brain washout (<0.03±0.01 % ID/g after 1 h) and clearance from 
blood, liver, kidney and highly irrigated organs (Table3). Taking in consideration that brain uptake 
higher than 0.1 % ID/g has been accepted as the percentage of base limit for existing BBB crossing 
46
, 
our PepH3 demonstrated a potent brain targeting, achieving in some cases higher values than the ones 
obtained for known peptides design for brain-targeted delivery. For instance, the peptides Amylin, 
Insulin, PYY3-36 and Secretin present a brain uptake between 0.045 and 0.176 % ID/g 
47-50
. The 
Angiopeptides family 
51
, have similar brain penetration when compared with PepH3 (0.18-0.6 % ID/g), 
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yet this penetration degree was obtained through in situ brain perfusion in contrast with injection in the 
tail vein, a much more demanding condition. Other “high performance” BBB peptides-vectors such as 
TAT, penetratin, synB1 and others range from 0.2 to 0.9 % ID/g of tissue 
39
. The synthetic peptide 
K16ApoE presents the highest value of brain uptake, up to 1.14 % ID/g 
52
. In addition, antibodies that 
engage active RMT processes show similar translocation levels to PepH3 
17
 as observed for our control, 
FC5 (0.47±0.27 % ID/g). Furthermore, PepH3 is rapidly excreted in high percentages (36.0±11.2 % 
ID/g) when compared with FC5 (9.6±1.4 % ID/g), which is extremely positive to avoid toxic effects 
associated to accumulation in the brain. This property ensures that the peptide can be used as an active 
shuttle in-and-out the brain, not only as an active carrier to the brain. In neurodegeneration therapy, for 
instance, removing cytotoxic aggregates from brain may be as important as delivering drugs to the 
brain. The existence of molecular shuttles that are fit for both functions would be a major step forward 
for innovative therapeutic approaches. Our study paves the way for new strategies in CNS-targeted 
therapies. 
 
CONCLUSION 
Results of in vitro and in vivo assays have shown that selected DEN2C-derived peptides have high 
ability to cross the BBB. There is strong evidence that PepH3 efficiently penetrates the brain using 
AMT and return to blood circulation to be excreted.  Thus, PepH3 is a potential trans-BBB shuttle 
53
, 
potentially able to carry drugs from blood to brain and toxic cargo from brain to blood, which may lead 
to new therapeutic applications in the CNS field 
54
, such as Alzheimer or Parkinson Disease´s.  
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METHODS 
Peptides sequences were selected from particular domains of the Dengue virus capsid protein (Helical 
domains, underlined and listed in table 1), with the following sequence:  
MNDQRKKARNTPFNMLKRERNRVSTVQQLTKRFSLGMLQGRGPLKLFMALVAFLRFLTIPPTA
GILKRWGTIKKSKAINVLRGFRKEIGRMLNILNRRRR.  
FC5 antibody fragment  
16, 55
 was synthesized by Nzytech (Lisbon, Portugal)  
Materials. All N-α-FMOC-protected amino acids, MBHA Rink Amide resin, O-(Benzotriazol-1-yl)-
N,N,N’,N’-tetramethyluronium hexafluorophosphate (HBTU) and N-[(Dimethylamino)-1H-1,2,3-
triazolo-[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide 
(HATU) were purchased from Novabiochem (Merck, Lisbon, Portugal). 
4-((3-(4-(2-tert-butoxy-2-oxoethyl)-3,5-dimethyl-1H-pyrazol-1-yl)ethyl)(2-tert-butoxycarbony-
lamino)ethyl)-amino)butanoic acid (t-buPz
1
(Boc)) and 1-(2-((2-tert-butoxycarbonylamino)ethyl)(3-
carboxypropyl)amino)ethyl)-1H-pyrazole-4-carboxylic acid (Pz
2
(Boc)) were synthesized  as described 
in Morais et al 2013 
56
. The macrocyclic bifunctional chelator 4-(4,7-bis(2-(tert-butoxy)-2-oxoethyl)-
1,4,7-triazacyclononan-1-yl)-5-(tert-butoxy)-5-oxopentanoic acid (NODA-GA(tBu)3) was purchased 
from CheMatech (Dijon, France). 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholineserine (POPS), 1-palmitoyl-2-oleoyl-sn-glycero-3-
phospho-(19-sn-glcerol) (POPG) and cholesterol were obtained from Avanti Polar Lipids (Netherlands). 
4-(2-[6-(diocylamino)-2-naphthalenyl] etheny)-1-(3-sulfopryl)-pyridinium (di-8-ANEPPS) was obtained 
from Molecular Probes (Eugene, OR). 
The cell lines and media were obtained from American Type Culture Collection (ATCC, Manassas, 
USA). Fibronectin bovine plasma was obtained from CALBIOCHEM. Other consumables used in the in 
vitro assays were purchased from Gibco-Invitrogen. Tissue culture inserts and 24-well plates were 
obtained from BD falcon. All other chemical and solvents were either obtained from Merck or Sigma-
Aldrich. 
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Sodium pertechnetate (Na[
99m
TcO4]) was eluted from a 
99
Mo/
99m
Tc generator, using 0.9% saline. The 
precursor fac-[
99m
Tc(CO)3(H2O)3]
+
 was prepared using an Isolink kit and its radiochemical purity 
checked by RP-HPLC as previously described 
56
. 
Gallium-67 citrate (
67
Ga-citrate) was a gift from the nuclear medicine service of Hospital de Santa 
Maria (Lisbon, Portugal). 
67
GaCl3 was prepared from 
67
Ga-citrate (Mallinckrodt Medical, Netherlands) 
as described in the literature 
57
. 
Reverse Phase High Performance Liquid Chromatography (RP-HPLC) analysis. HPLC analyses 
were performed on a Perkin Elmer LC pump 200 coupled to a Shimadzu SPD 10AV UV/Vis and to a 
Berthold-LB 509 radiometric detector.  
Analytical control and semi preparative purifications of the peptides and peptide conjugates were 
achieved on Supelco Discovery Bio Wide Pore C18 Column (250 mm × 4.6 mm, 5 µm) and Supelco 
Discovery Bio Wide Pore C18 column (250 mm × 10 mm, 10 µm)) with a flow rate of 1.0 mL min
−1
 or 
2.0 mL min
−1
 (gradient B), respectively. In both cases, U.V. detection: λ = 220 nm and 280 nm; Eluents: 
A ‐ 0.1% TFA in H2O; B ‐ 0.1% TFA in CH3CN. 
Applied binary HPLC gradients: 
Gradient A (PepH1, PepH3 and corresponding conjugates): (Eluents: A ‐ 0.1% TFA in H2O; B ‐ 0.1% 
TFA in CH3CN) 0-25 min, 10-50% B; 25-27 min, 100% B; 27-28 min, 100-0% B; 28-30 min, 10% B. 
Gradient B (PepH2 and corresponding conjugate): (Eluents: A ‐ 0.1% TFA in H2O; B ‐ 0.1% TFA in 
CH3CN) 0-5 min, 50% B; 5-30 min, 50-100% B; 30-35 min, 100% B; 35-36 min, 100-50% B; 36-40 
min, 50% B. 
Gradient C (PepH4 and corresponding conjugate): (Eluents: A ‐ 0.1% TFA in H2O; B ‐ 0.1% TFA in 
CH3CN) 0-25 min, 10-70% B; 25-27 min, 100% B; 27-28 min, 100-0% B; 28-30 min, 10% B. 
Gradient D (
99m
Tc-labeled peptide conjugates): (Eluents: A ‐ 0.1% TFA in H2O; B ‐ 0.1% TFA in 
CH3CN) 0-3 min, 0% B; 3-3.1 min, 0-25% B; 3.1-9.0 min, 25% B; 9.0-9.1 min, 25-34% B; 9.1-14.1 
min, 34-100% B; 14.1-19.0 min, 100% B; 19.0-21.0 min, 100% B; 21-30 min, 0% B. 
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Gradient E (
67
Ga-labeled peptide conjugates): (Eluents: A ‐ 0.1% TFA in H2O; B ‐ 0.1% TFA in 
CH3CN) 0.0-3.0 min, 0% B; 3.0-3.1 min, 0-10% B; 3.1-19.9 min, 10-100% B; 19.9-22.0 min, 100% B; 
22.0-23.0 min; 100-0%; 23.0-30.0 min, 0% B.  
Synthesis of the peptides. The peptides (Table 1) were assembled on Rink Amide MBHA resin by 
Fmoc-based solid phase peptide synthesis (SPPS) in a CEM 12-channel microwave assisted automated 
peptide synthesizer (Liberty). After cleavage from the resin, semi preparative RP-HPLC purification and 
lyophilization (following gradients described above), the peptides were obtained as white solids. 
Finally, the peptides were characterized by Electrospray Ionization Mass Spectrometry (ESI-MS) and 
their concentration determined by U.V. spectrophotometry.  
Synthesis of the peptide conjugates. The peptide-conjugates Pz
x
PepHY (x = 1 or 2; Y = 1-4) were 
prepared in solid support by conjugation of t-buPz
1
(Boc), Pz
2
(Boc) or NODA-GA(tBu)3 to the N-
terminal of each peptide sequence. Briefly, the protected chelating agent (2.5 equiv per amine on resin) 
was pre-incubated for 5 min with hydroxybenzotriazole (HOBt; 1.2 equiv per carboxylate) 
and   benzotriazole-l-yl-oxy-tris-pyrrolidino- phosphonium hexafluorophosphate (PyBop; 1.2 equiv per 
carboxylate). This solution was added to the peptidyl resin (ca 50 mg) previously suspended in 
dimethylformamide (DMF) and N,N-diisopropylethylamine (DIPEA; 1 equiv per amine group).  After 
stirring for 2 h at room temperature, the solvents were removed by filtration and the resin was washed 
with DMF (3X), CH2Cl2 (3x), DMF (3X) and CH2Cl2 (3x).  
Removal of the protecting group as well as cleavage of the peptide conjugates from the resin was 
performed using a standard cleavage cocktail (95% TFA, 2,5% TIS, 2,5% H2O). After stirring for 2 h at 
room temperature, the TFA solution was collected after removal of the resin by filtration. The solution 
was concentrated and the conjugate was precipitated with ice-cold diethyl ether. The solid was washed 
several times with ice-cold diethyl ether, dried under nitrogen flow before lyophilization. The 
lyophilized peptide conjugates were dissolved in 10% (v/v) acetic acid solution and purified by semi 
preparative RP-HPLC to yield the desired peptide conjugates that were characterized by ESI-MS and 
lyophilized.    
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Radiolabeling with [
99m
Tc(CO)3]
+
. The radiopeptides TcPz
x
PepHY (x = 1 or 2; Y = 1-4) were 
synthesized by reaction of the peptide-conjugates Pz
x
PepHY (x = 1 or 2; Y = 1-4) with the precursor 
fac-[
99m
Tc(CO)3(H2O)3]
+
, which was prepared using an Isolink kit and its radiochemical purity checked 
by RP-HPLC. Briefly, a solution of fac-[
99m
Tc(CO)3(H2O)3]
+
 (900 µL) was added to  a capped vial 
previously flushed with N2, containing a solution of peptide conjugate (100 µL, 1 mM). The mixture 
reacted for 30 min at 100 °C and the radiochemical purity of the radiopeptides was checked by RP-
HPLC (gradient D). The radiolabeled compound was purified by semi preparative RP-HPLC (gradient 
D). The activity corresponding to TcPz
x
PepHY (x = 1 or 2; Y = 1-4) was collected in a 50 mL Falcon 
flask, containing 200 µl of PBS with 0.2% BSA, and purged with N2 gas to remove the acetonitrile. The 
pH of the final solution was adjusted to 7.4 with 0.1 M NaOH for the cell and biodistribution studies. 
The final product was controlled by analytical RP-HPLC (gradient D). The control model complex 
TcPz
3
 was prepared as described by Alves et al 
58
.  In brief, TcPz
3
 was obtained upon reaction of the 
bifunctional chelator Pz
3
 (4-((2-aminoethyl)(2-(3,5-dimethyl-1H-pyrazolyl-1-yl)ethyl)amino)butanoic 
acid) with fac-[
99m
Tc(CO)3(H2O)3]
+
 at 100ºC for 30 min. 
Radiolabeling with 
67
Ga
3+
. The pH of a fraction (0.5 mL) of 
67
GaCl3 eluted from a SEP-PAK cartridge  
was adjusted to pH 5 by adding sodium acetate (18 mg). Part of this solution (190 µL, 370-420 MBq) 
was added to the peptide conjugate (10 µL, 1 mM ) and the mixture was incubated for 5 min at room 
temperature. The radiochemical purity of the radiopeptides 
67
Ga-NODAGA-PepHY 
(GaNODAGAPepHY, Y = 1 – 4) was checked by RP-HPLC (Gradient E).  
Partition coefficient. Octanol-water partition coefficient was evaluated by “shake-flask” method 
31
. 
Briefly, the radiopeptide conjugate was added to a mixture of octanol (1 mL) and 0.1 M PBS pH 7.4 (1 
mL), previously saturated with each other by stirring. This mixture was vortexed and centrifuged (300 
rpm, 10 min) to allow phase separation. Aliquots of both octanol and PBS were counted in a γ counter. 
The partition coefficient (Po/w) was calculated by dividing the counts in the octanol phase by those in the 
buffer.  
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Cell culture. bEnd.3 brain endothelioma cells (ATTCC-CRL-2299, Lot. 59618606) were grown in 
DMEM supplemented with 10 % fetal bovine serum (FBS) and 1 % penicillin/streptomycin antibiotic 
solution. Cells were cultured in a humidified atmosphere of 95% air and 5% CO2 at 37 °C (MCO-
19AIC (UV), Sanyo), with medium changed every other day. The cells were adherent in monolayers 
and, when confluent, were harvest from cell culture flasks with trypsin EDTA and seeded 3000 cell/well 
to fibronectin bovine plasma coated tissue culture inserts (pore size of 1 µm) for 24-well plates (BD 
falcon). To allow to form tight junctions and to have a stable in vitro model, cells were grown for 9 days 
and media changed every two days. Conditions were optimized from protocols described by others 
59
.  
BEB integrity assays. 1 µM of each unlabeled peptide solution in complete media was added to bEnd.3 
cells grown in tissue culture inserts (for 9 days, as described before) and incubated for 24 h. After 
incubation peptide solution was removed and cells washed once with PBS and 3 times with transport 
buffer (5mM glucose, 5mM MgCl2, 10 mM HEPES pH 7.4, and 0.05 % BSA). Fluorescent probes of 
5(6)-Carboxyfluorescein (FITC) with molecular weight (MW) of 376.32 Da and fluorescein 
isothiocyanate-dextran with MW of 4 and 40 KDa (FD4 and FD40, respectively) (all from sigma-
aldrich), were diluted in transport buffer to absorbance of 0.1, from stocks of 25 mg/ml. Probes were 
then added to the apical side (apex) and incubated for 2 h. Samples were collected from apex and base 
and fluorescence intensity was measured at λ of excitation of 493 nm and maximum emission at 560 nm 
in a plate reader (TECAN infinity M200).  
BEB in vitro model of translocation and cellular internalization. 5 µCi mL
-1
 of the radiopeptides was 
added to bEnd.3 cells grown in tissue culture inserts and incubated for different time points (15 min, 5 h 
and 24 h). After incubation, samples were collected from apex, base, and membrane. In addition, both 
base and apex were washed with 10 % DMSO in PBS. The washing samples were combined to the 
respective sample from the apical side and the base. The radioactivity in the samples collected from 
apical side, base and in the filter were measured in a γ-counter (LB211, Berthold, Germany) 
For the internalization and cellular interaction studies, 5 µCimL
-1
 of radiopeptides were added to bEnd.3 
cells growing in 24-well plates and incubated for 15 min, 5 h e 24 h. After incubation, cells were 
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washed with cold media, followed by 2-times acid wash (50 mM glycine, 100 mM NaCl, pH 2.8). After 
neutralization with PBS, cells were lysed (Lysis buffer: 1 M NaOH) and the cellular content collected. 
The radioactivity associated to each fraction was measured in the γ-counter.  
FC5 antibody domain preparation. DNA encoding the FC5 clone was synthesized by Nzytech adding 
a NheI and XhoI restriction sites at 5’ and 3’ ends, respectively, for cloning into pET21a(+) or pET28a 
plasmid (Novagen, Merck Millipore). A fragment encoding FC5-HIS-HA was generated by PCR (KOD 
Hot start Master Mix, Merck Millipore) and then purified (QIAquick Gel extraction Kit, Qiagen), 
followed by insertion into the expression vector. The expression vector containing the gene of interest 
was then transformed into bacterial strain BL21(DE3) (Nzytech). An isolated colony with gene of 
interest (confirmed by sequencing), was used to prepare stocks and to express the protein in selective 
media (super broth (SB) containing Ampicillin). Protein expression was induced by addition of 1 mM 
isopropyl 1-thiol-β-D-galactopyranoside (IPTG) to a culture with A600nm = 0.6 at 37 °C, after induction 
the bacteria were grown 16 h at 16 °C. Cells were harvested by centrifugation and ressupended in 50 
mM Sodium phosphate, 1 M sodium chloride, 10 % Glycerol, pH 6.8. The pellet was sonicated at 4 °C 
during 20 min and centrifuged at 10 000 rpm for 30 min, 4 °C. Supernatant was purified by immobilized 
metal affinity chromatography (IMAC), using HP Histrap columns and AKTA FPLC system (GE 
Healthcare). After purification, the purity (>95%) of the eluted samples was analyzed by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).  
Radiolabeling of FC5 antibody domain. The radiolabeled protein 
99m
Tc(CO)3-FC5 (TcFC5) was 
prepared by reacting the recombinant antibody with fac-[
99m
Tc(CO)3(H2O)3]
+
. Briefly, a specific volume 
of the fac-[
99m
Tc(CO)3(H2O)3]
+
 solution was added to a  nitrogen-purged closed glass vial containing a 
solution of the His-tag containing FC5  VHH antibody in order to get a final concentration of 1 mg/ml.  
In order to avoid undesired aggregation of the protein, an adequate volume of a 10 % SDS solution was 
added in order to reach a final concentration of 0.5%. The mixture reacted for 30 min at 37 ºC and the 
radiochemical purity of  TcFC5 was checked by instant thin-layer chromatography silica gel (ITLC-SG, 
Varian) analysis using a 5% HCl (6 M) solution in MeOH as eluent. [
99m
Tc(CO)3(H2O)3]
+
 and [TcO4]
-
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migrate in the front of the solvent (Rf = 1), whereas  the radioactive antibody remain at the origin (Rf = 
0).  Radioactivity distribution on the ITLC-SG strips was detected by a radioactive scanner (Berthold 
LB 2723, Germany) equipped with 20 mm diameter NaI(Tl) scintillation crystal. Purification of the 
99m
Tc-labeled antibody was performed using Amicon
®
 (10 K, Merck Millipore) centrifugal filters for 
protein purification and concentration following the procedure of the supplier. The supernatant is 
discarded and the pellet containing TcFC5 was ressuspended in 100 µL PBS and used in the 
biodistribution studies in mice. The radiochemical purity (> 95 %) was determined by ITLC-SG. 
Biodistribution. All animal experiments were performed in compliance with national and European 
regulations for animal experimentation. The animals were housed in a temperature and humidity 
controlled room with a 12 h light/12 h dark schedule. Biodistribution of radiopeptides was performed on 
CD1 mice.  
Animals were intravenously injected into tail vein with the radiolabeled compound diluted in 100 µL 
PBS pH 7.2 (TcPz
3
: ca. 6.5 MBq/mouse, ca. 1911 MBq/mg; TcPz
1
PepH1: ca. 6.9 MBq/mouse, 60 
MBq/mg; TcPz
1
PepH3: ca. 0.4 MBq/mouse, ca. 3.1 MBq/mg; TcFC5: ca. 3.8 MBq/mouse). The mice 
were sacrificed by cervical dislocation at 5 min and 1 h after injection. The dose administered and the 
radioactivity in the sacrificed animals was measured using a dose calibrator (Carpintec CRC-15W, 
Ramsey, USA). The difference between the radioactivity in the injected and the euthanized animals was 
assumed to be due to excretion. Brain and tissues of interest were dissected, rinsed to remove excess 
blood, weighed, and their radioactivity measured using a γ-counter. The uptake in the brain and tissues 
of interest was calculated and expressed as a percentage of injected radioactivity dose per gram of tissue 
(%ID/g).  
In vivo stability. The stability of the complexes was assessed by RP-HPLC analysis of urine and blood 
serum, under identical conditions to those used to analyze the original radiopeptides. The samples were 
collected 5 min and 1 h after injection. The urine collected at the time of sacrifice and filtered through a 
Millex GV filter (0.22 µm) before analysis. Blood collected from mice was centrifuged at 3000 rpm for 
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15 min at 4 °C, and the serum separated. The serum was treated with ethanol in a 2:1 (v/v) ratio to 
precipitate the proteins. After centrifugation, the supernatant was collected and analyzed by RP-HPLC. 
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SUPPORTING INFORMATION PARAGRAPH  
 
Supplemental Figures S1 & S2 display the biophysical studies of peptide interaction with membrane 
models.   
Supplemental Figure S3 shows the results of cell viability assays. 
Supplemental Table S1 details the percentage of transmigration of the transwell cellular BBB model, 
and cellular adsorption and internalization at 15 min, 5 h and 24 h.  
 
 
FIGURE CAPTIONS  
Figure 1 – Dengue virus capsid protein (DEN2C) sequence. DEN2C is a 12 kDa protein, with 100 
amino acid residues. The protein is formed by 4-helical domains, α1, α2, α3, and α4, designated PepH1, 
PepH2, PepH3 and PepH4, respectively. 
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Figure 2 – Determination of BEB integrity in the presence of peptides. The in vitro BEB model 
consists of a transwell system with an insert in which bEnd.3 cells are grown separating two chambers 
(A). The insert, or apical side, corresponds to the blood side, while the base (bottom chamber) 
corresponds to the brain side. Unlabeled peptides (1 µM) were added to the top compartment. After 24 h 
peptide addition, the fluorescence emission intensity of probes having different molecular weights 
(FITC with 376.32 Da, FD4 with 4 KDa and FD40 with 40 KDa) was registered from the base 
compartment, and compared to two controls: one with the naked transwell filter (marked “Filter”) and 
other consisting of the fluorescence intensity of the stock solution after stirred dilution (marked 
“Stock”). Represented values were obtained from triplicates of two independent experiments.  
Figure 3 – Kinetics of translocation of the transwell in vitro model of the BEB. 5 µCi ml
-1
 of 
radiopeptides (TcPz
x
PepH1 to TcPz
x
PepH4, x = 1 or 2) were initially added to the apical side. After 15 
min, 5 h and 24 h incubation the relative amount of PepH1 (A), PepH2 (B), PepH3 (C), and PepH4 (D) 
in the apical side plus filter cells (black bars) and base (white bars) were quantified. The amount in the 
apex and base was normalized to the initial total amount of labeled peptide added to the top and 
expressed as the percentage of recovered radioactive dose. PepH1, PepH3, and PepH4 are efficient in 
BEB translocation, whereas PepH2 has limited passage through the BBB. Values obtained from 
triplicates of two independent experiments.  
Figure 4 – Radiopeptide uptake by bEnd.3 cells. The relative amount of noun-bound radiopeptides in 
solution (black bars), released cells treated with acid buffer (membrane adsorption assay; white bars) 
and in cell lysate (internalization; striped bar) was determined for radiopeptides (TcPz
x
PepH1 to 
TcPz
x
PepH4, x = 1 or 2): PepH1 (A); PepH2 (B); PepH3 (C); and PepH4 (D), at 15 min, 5 h and 24 h 
after peptide addition. The radioactivity intensity was normalized to the initial value added to cells and 
expressed as percentage of recovery. PepH1 and PepH3 had no interaction with cell membrane or 
internalization (lower than 0.6 and 0.4 % at 24 h, respectively), while PepH2 showed strong interaction 
with cell membrane at 5 h (5.95 %) and high internalization at 24 h (42.7 %). PepH4 has moderate 
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membrane interaction and low internalization (10.23 and 2.83 % at 24 h, respectively). Values obtained 
from triplicates of two independent experiments.  
Figure 5 – Chemical stability of 
99m
Tc(CO)3-labeled PepH1 and PepH3 in blood and urine. RP-
HPLC γ traces of radiopeptides in blood serum (A and C) and urine samples (B and D) collected after 5 
min and 1 h after injection.  
 
TABLES 
Table 1 – (Radio)peptide properties.  Peptide sequences, isoelectric point (IP), charge, molecular 
weight (MW), HPLC retention time, and octanol-water partition coefficients for all peptide derivatives.  
Table 2 – Determination of BEB translocation, membrane adsorption and internalization of 
radiopeptides in bEnd.3 cells. Recovered radioactivity of peptides labeled with TcPz
x
 or GaNODA 
after 24 h incubation, in the base.   
Table 3 – Biodistribution profiles of 
99m
Tc(CO)3-labeled peptide-vectors and small domain 
antibody FC5. Tissue distribution of TcPz
3
, TcPz
1
PepH1, TcPz
1
PepH3 and TcFC5 at 5 min and 1 hour 
post injection via tail vein in CD1 mice. Results are expressed as the average of percentage of injected 
dose (ID) per gram of tissue (%ID/g tissue) (mean ± SD), n = 3.  
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